Recent News

• 06.03.2025 - Genprex to Participate at BIO 2025 International Convention
• 05.29.2025 - Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
• 05.28.2025 - Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
• 05.07.2025 - Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
• 05.06.2025 - Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
• 04.30.2025 - Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
• 04.29.2025 - Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
• 04.28.2025 - Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
• 04.24.2025 - Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
• 04.22.2025 - Genprex Announces Research Collaborators’ Abstract Published in Cancer Research Supplement Proceedings

Recent Filings

• 05.14.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2025 - 8-K Current report
• 05.06.2025 - 8-K Current report
• 04.28.2025 - 8-K Current report
• 04.24.2025 - DRS Draft Registration Statement
• 04.01.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.01.2025 - NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405